axicabtagene ciloleucel
gilead sciences,daiichi sankyo
['lymsm', 'zuma-7', 'dlbcl', 'axi-cel']
our poster of patients with r/r dlbcl in zuma-7 who are 65y+ found excellent outcomes and rapid improvement in quality of life with axi-cel compared to soc chemo. #asco22 #lymsm 
Director of Clinical Research, Section Chief of Aggressive Lymphomas @MDAndersonNews, @ASCO Board member & Govt Relations Committee Chair-elect, Opinions mine